Salvage Treatment After rInterferon α-2a in Advanced Neuroendocrine Tumors

References

• Pearse A G. The cytochemistry and ultrastructure of polypeptide hormone producing cells of the APUD series and the embryologic, physiologic and pathologic implications of the concept. J Histochem Cytochem 1969; 17: 303–13
   PubMed Web of Science ®Google Scholar
• Öberg K, Funa K, Aim G. Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with midgut carcinoid tumors and carcinoid syndrome. N Eng J Med 1983; 309: 129–33
   PubMed Web of Science ®Google Scholar
• Moertel C G, Rubin J, Kvols L K. Therapy of metastatic carcinoid tumor and the malignant carcinoid syndrome with recombinant leukocyte α interferon. J Clin Oncol 1989; 7: 865–8
   PubMed Web of Science ®Google Scholar
• Smith D B, Scarffe J H, Wagstaff J, Johnston R J. Phase II trial of rDNA α2b interferon in patients with malignant carcinoid tumor. Cancer Treat Rep 1987; 71: 1265–6
   PubMedGoogle Scholar
• Moertel C G. Clinical management of advanced gastrointestinal cancer. Cancer 1975; 36: 675–82
   PubMed Web of Science ®Google Scholar
• Moertel C G. Treatment of the carcinoid tumor and the malignant carcinoid syndrome. J Clin Oncol 1983; 1: 727–40
   PubMed Web of Science ®Google Scholar
• Engstrom P F, Levin F T, Moertel C G, Foisch E, Douglas H O. Streptozotocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. J Clin Oncol 1984; 2: 1255–9
   PubMed Web of Science ®Google Scholar
• Schein P S, O'Connel M J, Blom J, et al. Clinical antitumor activity and toxicity of streptozotocin (NSC-85998). Cancer 1974; 34: 993–1000
   PubMed Web of Science ®Google Scholar
• Moertel C G, Hanley J A. Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Clin Cancer Trials 1979; 2: 327–34
   PubMedGoogle Scholar
• Bukowski R M, Johnson K G, Peterson R F. A phase II trial of combination chemotherapy in patients with metastatic carcinoid tumors. Cancer 1987; 60: 2891–5
   PubMed Web of Science ®Google Scholar
• Frame J, Kelsen D, Kemeny N, et al. A phase II trial of streptozotocin and adriamycin in advanced APUD tumors. Am J Clin Oncol 1988; 11: 490–5
   PubMed Web of Science ®Google Scholar
• Abrams R A, King D, Wilson F. Objective response of malignant carcinoid to radiation therapy. Int J Radiat Oncol Biol Phys 1987; 13: 869–73
   PubMedGoogle Scholar
• Shapiro B. Summary, conclusions, and future directions of (131 I)-Metaiodo-benzylguanidine therapy in the treatment of neural crest tumors. J Nucl Biol Med 1991; 35: 357–63
   PubMedGoogle Scholar
• Hoefnagel C A, den Hartog Jager F CA, Taal G B, Abeling N GGM, Engelsman E E. The role of 131 I-MIBG in the diagnosis and therapy of carcinoids. Eur J Nucl Med 1987; 13: 187–91
   PubMedGoogle Scholar
• Von Moll L, McEwan A J, Shapiro B, et al. Iodine-131 MIBG scintigraphy of neuroendocrine tumors other than pheochromocytoma and neuroblastoma. J Nucl Biol Med 1987; 28: 979–88
   Google Scholar
• Adolph J, Kimmig B, Eisenhut M, Georgi P. Therapy of carcinoid tumors with 131 I-meta-iodo-benzyl-guanidine. Recent results. Cancer Res 1988; 110: 280–4
   Google Scholar
• Bestagno M, Pizzocaro C, Pagliaini R, Rossini P L, Guerra P. Results of (131 I) metaiodobenzylguanidine treatment in metastatic carcinoid. J Nucl Biol Med 1991; 35: 343–5
   PubMedGoogle Scholar
• Hoefnagel C A, Taal B G, Valdes Olmos R A. Role of (131 I) metaiodobenzylguanidine therapy in carcinoids. J Nucl Biol Med 1991; 35: 346–8
   PubMedGoogle Scholar
• Castellani M R, Di Bartolomeo M, Maffioli L, Zilembo N, Gasparini M, Buraggi G I. (131 I) metaiodobenzylguanidine therapy in carcinoid tumors. J Nucl Biol Med 1991; 35: 349–51
   PubMedGoogle Scholar
• Colombo L, Vignati A, Lomuscio G, Dottorini M E. Preliminary results of (131 I) metaiodobenzylguanidine treatment in metastatic carcinoid tumors. J Nucl Biol Med 1991; 35: 352–4
   PubMedGoogle Scholar
• WHO/UICC Handbook for reporting results of cancer treatment. WHO Offset publication no. 48, Geneve 1978
   Google Scholar
• McEwan A JB. Treatment of patients with metastatic carcinoid tumor with (131 I)-Metaiodobenzylguanidine: Abstract book of the ‘International Workshop on the role of (131 I) Metaiodobenzylguanidine in the treatment of neural crest tumors’. Rome (Italy, September 6–7) Sorin Biomedical 1991; 56
   Google Scholar
• Stolinsky D C, Sadoff L, Braunwald J, Bateman J R. Streptozotocin in the treatment of cancer. Phase II study. Cancer 1972; 30: 61–7
   PubMedGoogle Scholar
• Feldman J M, Quickel R E, Murocek R L, et al. Streptozotocin treatment of metastatic carcinoid tumors. South Med J 1972; 65: 1325–7
   PubMedGoogle Scholar
• Moertel C G, Rubin J, O'Connel M. Phase II study of cis-platin therapy in patients with metastatic carcinoid tumors and malignant carcinoid syndrome. Cancer Treat Rep 1986; 70: 1458–60
   Google Scholar
• Chernicoff D, Bukowski R M, Groppe C W, Hewlett J S. Combination chemotherapy for islet cell carcinoma and metastatic carcinoid tumors with 5-fluorouracil and streptozotocin. Cancer Treat 1979; 63: 795–6
   PubMedGoogle Scholar
• Rougier P, Oliveira J, Ducrex M, Theodore C, Kac J, Droz J P. Metastatic carcinoid and islet cell tumors of the pancreas: a phase II trial of the efficacy of combination chemotherapy with 5-fluorouracil, doxorubicin and cisplatin. Eur J Cancer 1991; 27: 1380–2
   PubMed Web of Science ®Google Scholar
• Moertel C G, Kvols L K, O'Connel M, Rubin J. Treatment of neuroendcorine carcinomas with combined etoposide and cisplatin. Cancer 1991; 68: 227–32
   PubMed Web of Science ®Google Scholar
• Moertel C G, Lefkopoulo M, Lipsitz S, Hahn R G, Klaasen D. Streptozotocin-doxorubicin, streptozotocin-fluorouracil, or chlorozotocin in the treatment of advanced islet cell carcinoma. N Engl J Med 1992; 326: 519–23
   PubMed Web of Science ®Google Scholar
• Feun L G, Savaraj N, Legha S S, Silva E G, Benjamin R S, Burgess M A. Chemotherapy for metastatic Merkel cell carcinoma. Cancer 1988; 62: 683–5
   PubMed Web of Science ®Google Scholar
• Wynne C J, Kearsley J H. Merkel cell tumor. A chemosensitive skin cancer. Cancer 1988; 62: 28–31
   PubMed Web of Science ®Google Scholar